Palleon Pharmaceuticals to Present on Development of HLX316/E-688 at AACR Annual Meeting on April 03, 2026 AACR B7-H3-targeted sialidase HLX316 Immunotherapy for cancer Palleon +
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact on January 13, 2026 Autoimmune cardiometabolic Eli Eli Lilly Immunotherapy for cancer InduPro * * Inflammatory disorder M&A Neoplasms Neuroinflammation NLRP3 inhibitors Obesity Ventyx Biosciences VTX3232 VTX958 +
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact on January 12, 2026 Autoimmune cardiometabolic Eli Eli Lilly Immunotherapy for cancer InduPro * * Inflammatory disorder M&A Neoplasms Neuroinflammation NLRP3 inhibitors Obesity Ventyx Biosciences VTX3232 VTX958 +
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact on January 12, 2026 Autoimmune cardiometabolic Eli Eli Lilly Immunotherapy for cancer InduPro * * Inflammatory disorder M&A Neoplasms Neuroinflammation NLRP3 inhibitors Obesity Ventyx Biosciences VTX3232 VTX958 +
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact on January 09, 2026 Autoimmune cardiometabolic Eli Eli Lilly Immunotherapy for cancer InduPro * * Inflammatory disorder M&A Neoplasms Neuroinflammation NLRP3 inhibitors Obesity Ventyx Biosciences VTX3232 VTX958 +
ViVac Pharma Appoints Keren Leshem as CEO to Advance RNA-LNP Cancer Immunotherapy on November 21, 2025 Appointments Biotechnology CEO Immunotherapy for cancer Keren Leshem Leadership RNA-LNP ViVac Pharma +
Merck Wins FDA Approval for Subcutaneous Keytruda as Exclusivity Challenges Approach on September 22, 2025 Approved Biosimilars checkpoint inhibitors Immunotherapy for cancer Keytruda Keytruda Qlex Merck patent expiration Solid Neoplasm Subcutaneous Injections United States Food and Drug Administration +
BioNTech Acquires CureVac to Advance mRNA Cancer Therapies and End Patent Disputes on June 18, 2025 Acquisition BioNTech biotech merger COVID19 (disease) CureVac Immunotherapy for cancer Legal patent merger RNA, Messenger Vaccines +
Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal on June 04, 2025 Antibodies, Bispecific BioNTech BNT327 Immunotherapy for cancer milestone payments Myers Partnership PD-L1 Solid Neoplasm squibb Vascular Endothelial Growth Factor A +
Oncology Market in 2025: Innovation, Growth, and Patient-Centric Care on April 07, 2025 Artificial Intelligence Biosimilars Clinical Trial Design Combined Immunotherapy for cancer Neoplasms Personalized cancer care Precision Medicine targeted therapies +
Oncology Market in 2025: Innovation, Growth, and Patient-Centric Care on March 05, 2025 Artificial Intelligence Biosimilars Clinical Trial Design Combined Immunotherapy for cancer Neoplasms Personalized cancer care Precision Medicine targeted therapies +
Merck & Co. Partners with Epitopea to Explore 'Junk DNA' for Novel Cancer Antigens on February 20, 2025 Cryptigen CryptoMap platform DNA Epitopea heroin Immunotherapy Immunotherapy for cancer Merck & Co. tumor-specific antigens +